Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Free Cash Flow for 8 consecutive years, with -$89.3 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 12.13% year-over-year to -$89.3 million; the TTM value through Mar 2026 reached -$244.0 million, down 1.68%, while the annual FY2025 figure was -$234.3 million, 13.02% down from the prior year.
  • Free Cash Flow hit -$89.3 million in Q1 2026 for Kymera Therapeutics, down from -$66.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$3.6 million in Q4 2023 and bottomed at -$89.3 million in Q1 2026.
  • Average Free Cash Flow over 5 years is -$48.5 million, with a median of -$47.0 million recorded in 2024.
  • Year-over-year, Free Cash Flow skyrocketed 91.03% in 2023 and then crashed 1651.96% in 2024.
  • Kymera Therapeutics' Free Cash Flow stood at -$39.9 million in 2022, then surged by 91.03% to -$3.6 million in 2023, then plummeted by 1651.96% to -$62.7 million in 2024, then dropped by 6.59% to -$66.9 million in 2025, then tumbled by 33.54% to -$89.3 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$89.3 million, -$66.9 million, and -$27.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.